

QIBA CT Angiography Biomarker Committee (BC) Call

25 October 2022 at 11 AM CT

Call Summary

In Attendance

Andrew Buckler, PhD (Co-Chair)	Mathis Konrad, MSc	Nancy Obuchowski, PhD
Julius L. Decano, MD	Hugo Marques, MD, PhD	Edwin J.R. van Beek, MD, PhD
James Kevin DeMarco, MD	Alastair J. Moss, MD, PhD	Todd Villines, MD-INMD
Márton Kolossváry, PhD	James Mulshine, MD	

RSNA Staff

Julie Lisiecki

Moderator: Andrew Buckler, PhD

Discussion topics:

- Review of Profile edits made
- Planning for Clinical Feasibility Testing

Profile edits reviewed:

- Field of View (FOV) wording:
 - FOV must be large enough to encompass all of the thorax though this might increase radiation dose
 - A satisfactory resolution is needed for this question
 - There may be legal reasons to make a statement related to incidental findings, though these findings may not pertain to the quantitation
 - Not every clinical CT will be done with ultra-microscopy; so, a disclaimer may be needed
- If shall statements do not fit, the requirement may not be needed
- **Suggested wording for reconstruction:** “An optimal FOV shall be reconstructed for quantitation, where that recon shall be the smallest FOV that encompasses the vascular bed being quantified. At least one series shall ensure the FOV spans the available scan volume for assessment of incidental findings.”
- **Suggested wording for Physicist/acquisition device:** “Shall validate that the protocol achieves an f50 value greater than 0.35 line pairs per mm for both air and soft tissue edges. See section 4.1 Assessment Procedure: In-plane Spatial Resolution

Decisions / Action items (some ongoing):

- [Dr. DeMarco](#) provided questions that require the expertise of [Dr. Samei](#)
- [Dr. Samei](#) needed for next call if he is available
- Feasibility testing underway (advancement to Stage 3)
 - Drs. Kolossváry and Marques (coronary) expertise
 - Dr. DeMarco (carotid expertise)
- [Dr. Buckler](#) to update and distribute checklist in Excel spreadsheet format
- [Dr. Buckler](#) to share details re: Metrology articles
- Discussion of the field test (feasibility of the Profile) to be continued on the next call
- Questions or comments regarding the Profile may be directed to: [Drs. Buckler](#), [Saba](#), and [Schoepf](#).

Links for more information:

- [Profile Stages](#) | [CTA Profile \(March 2020 version\)](#) | [Public Comment Resolution Page](#)
- [CTA BC wiki](#) | [FDA Medical Device Development Tools](#)

Next call: Tuesday, December 6th at 11 am CT (Calls will resume after the RSNA Annual Meeting)